Journal Information
Vol. 26. Issue 7.
Pages 292-296 (October 1990)
Share
Share
Download PDF
More article options
Vol. 26. Issue 7.
Pages 292-296 (October 1990)
Full text access
Poliquimioterapia secuencial (carboplatino/vp-16) versus alternante (carboplatino/vp-16 y ciclofosfamida/vincristina/adriamicina) en el carcinoma microcítico de pulmón
Sequential polychemotherapy (carboplatinum/VP-16) vs alternating (carboplatinum/VP-16) and cyclophosphamide/vincristine/adriamicine in the treatment of microcytic carcinoma of the lung
Visits
4347
J. Sánchez de Cos Escuín, F. Masa Jiménez, J.L. de la Cruz Ríos, A. Martínez Verdasco
Unidad de Neumología. Servicio de Medicina Interna. Hospital de la S.S. San Pedro de Alcantara. Cáceres
This item has received
Article information

Se analizan los resultados obtenidos en el tratamiento del carcinoma microcítico de pulmón mediante 2 pautas de poliquimioterapia: A (secuencial: 6 ciclos de carboplatino y VP16, intervalados cada 21 días) y B (alternante: ciclos 1, 3 y 5 iguales al anterior y ciclos 2, 4 y 6 con ciclofosfamida, vincristina y adriamicina). Resultaron evaluables 37 pacientes: 24 de la pauta A y 13 de la B. Se obtuvo un 100% de respuestas globales (40% de respuestas completas [RC] y 60% de parciales [RP]) en casos de enfermedad limitada con ambos regímenes. En casos de enfermedad extendida, hubo un 78,5% de respuestas globales con la pauta A (21,4% RC y 57,1% RP) y 87,5% con la B (25% RC, y 62,5% RP). Aunque las tasas de respuesta fueron similares, la pauta B fue mejor tolerada, permitiendo un mayor grado de cumplimiento de la dosis (diferencia estadística casi significativa: p < 0,1). Sólo hubo un fallecimiento debido a citostáticos (pauta A) y los efectos tóxicos graves fueron escasos en ambos grupos.

We analyze the results obtained in the treatment of the microcytic carcinoma of the lung using two types of polychemotherapy: A (sequential: 6 cycles of carboplatinum and VP-16 with 21 days interval between them) and B: (alternating: cycles number 1,3, and S identical to the previous schedule and cycles number 2,4, and 6 with cyclophosphamide, vincristine and adriamicine). We included for the analysis 37 patients: 24 with A model and 13 with type B. In cases of limited disease we obtained a 100% of responses (40% of complete response (CR) and 60% of partial result (PR)) using both regimes. In cases of disseminated illness we observed 78.5 of global responses with model A (21.4% CR and 57.1 PR) and 87.5 with type B (25% CR and 62.5% PR). The regime B was more well tolerated than model A and although the rates of response were comparable, patients treated with model B had a higher degree of fulfilment of the doses (differences nearly significant: p< 0.1). We observed a death dne to the cytostatic treatment in schedule A. The toxic effects were scanty in both groups of patients.

Full text is only aviable in PDF
Bibliografía
[1.]
J. García Conde, V. Alberola, A. Lluch.
Avances en el tratamiento del carcinoma microcítico de pulmón.
En: Avances en Medicina Interna, (1988), pp. 79-88
[2.]
A. Ordóñez Gallego, C. García Girón, J. Feliu Batlle.
Estado actual en el tratamiento del carcinoma broncopulmonar de células pequeñas.
Arch Bronconeumol, 24 (1988), pp. 15-20
[3.]
B.E. Johnson, J.D. Minnu.
Small cell lung cancer.
En: Pulmonary diseases and disorders. Fishman AP, 2a 3d. Mc Graw-Hill, (1988), pp. 1971-1981
[4.]
C. Boni, G. Cocconi, G. Buragui, et al.
Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer.
Cancer, 63 (1989), pp. 638-642
[5.]
J. Vicente, G. Martín, J. Feliu, et al.
Carcinoma microcítico de pulmón.
Quimioterapia alternante más radioterapia. Regímenes A/ifosfamida, vincristina B/carboplatino, ciclofosfamida, VP-16. Resultados preliminares. II Congreso Nacional de Oncología Médica, (1989),
[6.]
P.I. Clark, M.L. Slevin.
Small cell lung cancer: Single agents revisted.
Respir Med, 83 (1989), pp. 381-382
[7.]
S.G. Spiro.
La quimioterapia en el cáncer pulmonar de células pequeñas.
Br Med J (ed esp), 1 (1986), pp. 17-20
[8.]
J. Sánchez de Cos, J. Redondo, A. Sever, A. García, J. De la Cruz, F. Masa.
Carcinoma broncopulmonar.
Estudio epidemiológico clínico de 157 casos. Atención Primaria, 6 (1989), pp. 304-311
[9.]
V.S. Prasad, A.R. Naylor, W.S. Walker, D. Lamb, E.W. Cameron, P.R. Walbaum.
Long term survival after pulmonary resection for small cell carcinoma of the lung.
Thorax, 44 (1989), pp. 784-787
[10.]
K. Karrer, H. Denck, P. Drings, J. Orel, M.F. Bruno.
Cooperative Group. Combination of surgery and chemotherapy for small-cell bronchial carcinoma.
Drugs Exp Res, 12 (1986), pp. 191-200
[11.]
P.A. Bunn, A.S. Lichter, R.W. Makich, et al.
Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer.
Ann Intern Med, 106 (1987), pp. 655-662
[12.]
M.L. Perry, W.L. Baton, K.J. Propert, et al.
Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.
N Engl J Med, 316 (1987), pp. 912-918
[13.]
E. Nou, O. Brodin, J. Bergh.
A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens.
Cancer, 62 (1988), pp. 1079-1090
[14.]
W.K. Evans, R. Feld, N. Murray, et al.
The use of VP-16 plus cisplatin during induction chemotherapy for small cell lung cancer.
Semin Oncol, 13 (1986), pp. 10-16
[15.]
L.H. Einhorn, J. Crawford, R. Birch, G. Omura, J. Johnson, F.A. Greco.
Cisplatin plus etoposide consolidation following cyclophosphamide doxorrubicin and vincristine in limited small cell lung cancer.
Jour Clin Oncol, 6 (1988), pp. 451-456
[16.]
I.G. Smith, T.J. Perren, M.J. Plant, et al.
Carboplatin.
VP-16 and ifosfamide, intensive chemotherapy for small cell lung carcinoma. Proc ECCO, 4 (1987), pp. 6
[17.]
M.J. Lindt, H. Anderson, D.B. Smitdh, et al.
Carboplatin, ifosfamide, etoposide with mid course vincristine and thoracic radiotherapy for limited stage small cell lung cancer.
Proc ECCO, 4 (1987), pp. 7
[18.]
V. Gatzeemeier, W. Achterath, M. Keckmayr, et al.
Pilot study with carboplatin/vincristine/etoposide as first line therapy in extensive small cell lung cancer.
Proc ECCO, 4 (1987), pp. 17
[19.]
J.M. Gracia, A. Querejeta, E. Esteban, et al.
Alternating scheme of chemotherapy with carboplatin (CBDCA) VP-16, ifosfamide, doxorrubicin and vincristine plus radiotherapy in the treatment of small cell lung cancer.
Preliminary results. Proc ECCO, 4 (1987), pp. 7
[20.]
Clemente MG, Muñiz MM, Escudero C, Molinos L, Ramos S, Martínez J. Carboplatino y etopósido asociados a radioterapia torácica como tratamiento primario del carcinoma broncogénico de célula pequeña (CBCP): experiencia en 47 casos tratados en una unidad de Neumología.
[21.]
M.B. Mc Illmurray, R.J. Bibby, B.E. Taylor, et al.
Etoposide compareed with the combination of vincristine, doxorrubicin and cyclpohosphamide in the treatment of small cell lung cancer.
Thorax, 44 (1989), pp. 215-219
[22.]
I.E. Smith, B.D. Evans, M.E. Gore, et al.
Carboplatin and etoposide as first line combination therapy for small cell lung cancer.
J Clin Oncol, 5 (1987), pp. 185-189
[23.]
J.R. Daniels, L.Y. Chak, B.I. Siric, et al.
Chemotherapy of small cell carcinoma of lung: A randomized comparison of altemating and secuential combination chemotherapy programs.
J Clin Oncol, 2 (1984), pp. 1191-1199
[24.]
K. Havemann, M. Wolf, R. Holle, et al.
Altemating versus secuential chemotherapy in small cell lung cancer.
Cancer, 59 (1987), pp. 1072-1082
[25.]
E.F. Smith, D.M. Carney, P. Harford, D.T. Sleijfer, P.E. Postmus.
A phase II study of oral etoposide in elderly patients with small cell lung cancer.
Thorax, 44 (1989), pp. 631-633
[26.]
E.F. Smith, D.M. Sleijfer, J. Meijer, N.H. Mulder.
Carboplatin and renal function.
Ann Intern Med, 110 (1989), pp. 1034
[27.]
A. Paredes, C. Pallarés, J.J. López, B. Ojeda, L. de Andrés, A.L. Pousa.
Fase II con carboplatino (CBDCA) en infusión de 24 h.
Tratamiento de primera línea en cáncer de pulmón de célula pequeña con enfermedad diseminada. II Congreso Nacional de Oncología, (1989),
[28.]
K. Havenmann, M. Wolf, R. Molle, et al.
Cyclic altemating chemotherapy in SCCL.
19th German Cancer Congress, (1988),
[29.]
J. Aisner, P. Alberto, J. Bitran, et al.
Role of chemotherapy in SCCL. A concensus report of the IASLC.
Cancer Treat Rep, 67 (1983), pp. 37-43
Copyright © 1990. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?